- Home
- ZIMV vs TYRA Comparison
ZIMV vs TYRA Comparison
Compare ZIMV & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZIMV
- TYRA
- Stock Information
- Founded
- ZIMV 2021
- TYRA 2018
- Country
- ZIMV United States
- TYRA United States
- Employees
- ZIMV N/A
- TYRA N/A
- Industry
- ZIMV Biotechnology: Electromedical & Electrotherapeutic Apparatus
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- ZIMV Health Care
- TYRA Health Care
- Exchange
- ZIMV Nasdaq
- TYRA Nasdaq
- Market Cap
- ZIMV 532.4M
- TYRA 571.9M
- IPO Year
- ZIMV N/A
- TYRA 2021
- Fundamental
- Price
- ZIMV $18.85
- TYRA $12.65
- Analyst Decision
- ZIMV Hold
- TYRA Strong Buy
- Analyst Count
- ZIMV 3
- TYRA 8
- Target Price
- ZIMV $14.50
- TYRA $31.00
- AVG Volume (30 Days)
- ZIMV 651.9K
- TYRA 231.5K
- Earning Date
- ZIMV 10-29-2025
- TYRA 11-06-2025
- Dividend Yield
- ZIMV N/A
- TYRA N/A
- EPS Growth
- ZIMV N/A
- TYRA N/A
- EPS
- ZIMV N/A
- TYRA N/A
- Revenue
- ZIMV $443,402,000.00
- TYRA N/A
- Revenue This Year
- ZIMV $2.49
- TYRA N/A
- Revenue Next Year
- ZIMV $1.26
- TYRA N/A
- P/E Ratio
- ZIMV N/A
- TYRA N/A
- Revenue Growth
- ZIMV N/A
- TYRA N/A
- 52 Week Low
- ZIMV $8.15
- TYRA $6.42
- 52 Week High
- ZIMV $19.01
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- ZIMV 76.07
- TYRA 62.48
- Support Level
- ZIMV $18.84
- TYRA $11.89
- Resistance Level
- ZIMV $19.01
- TYRA $13.24
- Average True Range (ATR)
- ZIMV 0.07
- TYRA 0.79
- MACD
- ZIMV -0.27
- TYRA 0.07
- Stochastic Oscillator
- ZIMV 5.88
- TYRA 82.01
About ZIMV ZimVie Inc.
ZimVie Inc is focused on the dental and spine markets and their respective growth drivers such as implants, surgical tools, bone graft substitutes, spinal fusion implants, non-fusion alternatives, and digital care management solutions. Business is organized into two operating segments the spine products segment and the dental products segment.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.